Lisa has over 16 years of experience in HEOR consulting and has led the strategy, planning, and execution of various global, multi-disciplinary programs. From early HEOR and HTA landscaping to global reimbursement programs, Lisa has successfully contributed to over 100 submissions, including NICE STAs, FTAs, HSTs, and MTAs.
Lisa's expertise includes guiding clients through complex challenges such as reimbursement for gene therapies, CAR-Ts, and immunotherapies. She excels in providing solutions that navigate rapidly evolving treatment landscapes.
Lisa holds a BSc in Human Biology from Loughborough University and a Diploma in Professional Studies.
Led clinical advisory boards, Delphi panels, and KOL interviews
Contributed to a utility vignette study.
Managed multi-million commercial deals
Including BIT, MAA, CDF, HST, and innovative pricing deals between the pharma industry and the NHS.
Published in the field of oncology
Extensive work across various therapy areas, from gene therapies to rare and ultra-rare diseases.
Experience in range of therapy areas:
Oncology
Cardiovascular and metabolic disorders
Inflammation, immunology, and rheumatology
Infectious diseases
Rare and ultra-rare diseases
Women’s health
Gastrointestinal, nephrology, and urology
Psychiatric conditions
Ophthalmology
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
